MedTrace Logo

Bleeding Time Study With AZD6482, Clopidogrel and ASA

NCT00853450 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2009-08-19

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.

Conditions

  • Antiplatelet Effect

Interventions

DRUG

AZD6482

Single intravenous infusion during a maximum of 5 hours

DRUG

Clopidogrel

Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.

DRUG

ASA

75 mg orally once daily during 7 days in each treatment arm

Sponsors & Collaborators

Principal Investigators

  • Peter Held · AstraZeneca Mölndal

  • Bo Fransson, MD · AstraZeneca Clinical Pharmacology Unit, Lund

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Completion
2009-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853450 on ClinicalTrials.gov